Synthetic lethality by targeting the RUVBL1/2-TTT complex in mTORC1-hyperactive cancer cells

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Mammalian target of rapamycin (mTOR) inhibitors show limited clinical success in cancer treatment.
• Cancer cells with hyperactive mTOR complex 1 (mTORC1) exhibit specific vulnerabilities.
• Identifying novel therapeutic targets is crucial for overcoming treatment resistance.

Purpose of the Study:

• To investigate the mechanism of piperlongumine, a selective inhibitor of mTORC1-hyperactive cancer cells.
• To define the role of the RUVBL1/2-TTT complex in cancer cell survival under mTORC1-driven stress.
• To explore RUVBL1/2 as a potential therapeutic target in mTORC1-addicted cancers.

Main Methods:

• Chemical library screening to identify piperlongumine's activity.
• Assessing piperlongumine sensitivity in cancer cells with varying mTORC1 activity.
• Investigating the interaction between piperlongumine, RUVBL1/2, and DNA damage pathways.
• Analyzing clinical cancer tissues for correlations between mTORC1 activity and RUVBL2 expression.

Main Results:

• Piperlongumine specifically targets cancer cells with high mTORC1 activity.
• Sensitivity to piperlongumine is dependent on the suppression of the RUVBL1/2-TTT complex.
• High mTORC1 activity, driven by c-Myc, increases DNA damage and reliance on RUVBL1/2 for survival.
• Clinical data show a positive correlation between high mTORC1 activity and RUVBL2 expression in tumors.

Conclusions:

• RUVBL1/2 acts as a crucial survival factor in cancer cells experiencing mTORC1-driven genotoxic stress.
• The mTORC1-Myc-DNA damage axis creates a dependency on RUVBL1/2 for cell survival.
• RUVBL1/2 represents a novel therapeutic target for cancers with hyperactive mTORC1 signaling.